The Readout

By  Damian Garde

Your guide to what’s new in biotech. Sign up for the newsletter here.

The READOUT
The Readout

Wall Street’s unwavering faith & Neurocrine’s sudden affordability

By Damian Garde

The READOUT
The Readout

Pick biotech’s best CEO & guess the bottom for Moderna

By Damian Garde

The READOUT
The Readout

Wall Street’s unicorn unfriendliness & biotech’s crowded future

By Damian Garde

The READOUT
The Readout

PhRMA’s diminishing returns & a new vaccine platform

By Damian Garde

The READOUT
The Readout

Moderna lands at last & pig skin for biotech

By Damian Garde

The READOUT
The Readout

Prison time for a legend & a VC firm on the defensive

By Damian Garde

The READOUT
The Readout

Moderna’s big day out & Vertex’s odds of making NICE

By Damian Garde

The READOUT
The Readout

Tesaro’s silver lining & Novartis’ big pricing reveal

By Damian Garde

The READOUT
The Readout

Gilead defends CAR-T & China’s ‘Kendall Square’ booms

By Damian Garde

The READOUT
The Readout

Your guide to the #CRISPRbabies saga & a controversial drug approval

By Damian Garde

The READOUT
The Readout

Celgene’s weighty weekend & a unicorn hits the road

By Damian Garde

The READOUT
The Readout

How Vir is spending its millions & business-unfriendly science

By Damian Garde

The READOUT
The Readout

A test for precision medicine & a Monday night news dump

By Damian Garde

The READOUT
The Readout

Gene-editing history & Ziopharm’s comeback strategy

By Damian Garde

The READOUT
The Readout

Your Friday news dump cheat sheet & super-specific sequencing

By Damian Garde

The READOUT
The Readout

Biotech’s M&A standoff & gene therapy monopolies

By Damian Garde

The READOUT
The Readout

Peanut allergies allayed & Chinese CAR-T data at ASH

By Damian Garde

The READOUT
The Readout

Gene therapy’s persistent problem & a record that might not matter

By Damian Garde

The READOUT
The Readout

Free* genome sequencing & biotech’s inexplicable dive

By Damian Garde

The READOUT
The Readout

Overselling the biotech dream & Celgene’s four-year low

By Damian Garde

The READOUT
The Readout

Pharma’s ‘influencer’ economy & the infinite Amarin debate

By Damian Garde

The READOUT
The Readout

Amarin’s big readout & a congressman’s biotech shares

By Damian Garde

The READOUT
The Readout

The fate of fish oil & a spicy biotech IPO

By Damian Garde

The READOUT
The Readout

Alnylam’s long road to profit & how to stitch a patent thicket

By Damian Garde

The READOUT
The Readout

The end of Sen. Celgene & following the money in biotech

By Damian Garde

The READOUT
The Readout

Drug pricing at the polls & Vivitrol’s market share

By Damian Garde

The READOUT
The Readout

Scaling gene therapy & repurposing PARP

By Damian Garde

The READOUT
The Readout

Alkermes’ bad day at the FDA & biotech’s seasonal malaise

By Damian Garde

The READOUT
The Readout

A spooky month for biotech & a mold-breaking IPO

By Damian Garde

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy